Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 341-349

Bentham Science Publishers

Access to resources Recommend Favorite

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

By Kang Byung   Kim Won   Kim Chul   Jang Geundoo   Lee Sung   Choi Yoon   Lee Dae   Kim Sang   Kim Shin   Ryu Jin-Sook   Huh Jooryung   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 516-522

Springer Publishing Company

Access to resources Recommend Favorite

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe   Milpied Noel  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite

High-dose chemotherapy regimen well tolerated in breast cancer

By  

Inpharma, Vol. 1, Iss. 1320, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite